This acquisition combines Officinae Bio's AI-enabled mRNA design platforms with Maravai and TriLink BioTechnologies' leading drug substance manufacturing capabilities, providing customers ...

Johns Hopkins scientists develop mRNA "booster" as potential new way to treat rare genetic diseases marked by too low levels ...

On February 24, Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) announced that it completed its acquisition of Officinae Bio’s DNA and RNA business, integrating AI-driven mRNA design technology with ...

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable ...

Johns Hopkins Medicine laboratory scientists say they have developed a potential new way to treat a variety of rare genetic ...

Everest Medicines has established a fully integrated and clinically validated mRNA platform, encompassing antigen design, mRNA sequence optimization, LNP delivery system, and GMP production ...

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a global leader in AI-powered antibody discovery and development, today announced a strategic collaboration with RIBOPRO, a ...

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in Descartes-08-treated participants in Phase 2b trial ...

The cancer vaccine candidate is manufactured with mRNA specific to these neoantigens found in that individual’s tumor. The process to design and manufacture individualized vaccines for cancer ...

Together, we intend to accelerate the field of next-generation medicines in mRNA and CRISPR ... we can now supercharge the design-build-test-learn cycle for our customers." Davide will continue ...

“By integrating our expertise in mRNA design and nanoparticle delivery with IPA’s cutting-edge antibody discovery and engineering capabilities, we can address longstanding challenges in ...